(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
6 November 2014 (06.11.2014)

WIPO | PCT

(10) International Publication Number
WO 2014/179453 A1

(51) International Patent Classification:
A61K 45/06 (2006.01) *A61P 3/06* (2006.01)
A61K 31/4025 (2006.01) *A61P 9/00* (2006.01)

(21) International Application Number:
PCT/US2014/036152

(22) International Filing Date:
30 April 2014 (30.04.2014)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/817,645 30 April 2013 (30.04.2013) US
61/824,199 16 May 2013 (16.05.2013) US

(71) Applicant: **ABBVIE, INC.** [US/US]; 1 North Waukegan Rd, AP06A - V0377, Chicago, IL 60064 (US).

(72) Inventors: **COLL CRESPO, Blas**; 289 Hastings Avenue, Highland Park, IL 60035 (US). **ANDRESS, Dennis**; 512 N. McClurg Court, #4110, Chicago, IL 60611 (US). **BRENNAN, Peter, J.**; 1709 Tall Pineway, Libertyville, IL 60048 (US). **STOLZENBACH, James, C.**; 278 Stanton Drive, Buffalo Grove, IL 60089 (US).

(74) Agents: **GETTEL, Nancy, J.** et al.; AbbVie, Inc., 1 North Waukegan Rd., AP06A - V0377, Chicago, IL 60064 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: METHODS FOR IMPROVING LIPID PROFILES USING ATRASENTAN




FIG. 1

(57) Abstract: The present disclosure is directed to methods for reducing cardiovascular risk in a human subject by administering atrasentan, or a pharmaceutically acceptable salt thereof, in an amount sufficient to effect a reduction of about 5% or more in one or both of (a) total serum cholesterol, relative to the subject's baseline total serum cholesterol, and (b) serum LDL cholesterol, relative to the subject's baseline serum LDL cholesterol.

WO 2014/179453 A1

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*